ArticleFrontiers in neurology2021
Time-Specific Pattern of Iron Deposition in Different Regions in Parkinson's Disease Measured by Quantitative Susceptibility Mapping.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Putamen iron quantification in diseases with neurodegeneration: a meta-analysis of the quantitative susceptibility mapping technique.Brain imaging and behavior · 2024Pooled it
- Technical Feasibility of Quantitative Susceptibility Mapping Radiomics for Predicting Deep Brain Stimulation Outcomes in Parkinson Disease.Neurosurgery · 2026Article
- In-vivo histology of Parkinson's disease using quantitative multiparametric mapping.NPJ Parkinson's disease · 2026Article
- Progressive iron deposition and widespread neural dysfunction in Parkinson's disease: a multimodal MRI study.Quantitative imaging in medicine and surgery · 2026Article
- The role of quantitative susceptibility mapping in dementia with Lewy Bodies.NeuroImage. Clinical · 2026Article
- Machine learning-based radiomics modeling of combined subcortical nuclei from quantitative susceptibility mapping for Parkinson's disease diagnosis.Frontiers in aging neuroscience · 2026Article
- Plasma α-synuclein and QSM-derived susceptibility in Parkinson's disease: associations with clinical features.Frontiers in aging neuroscience · 2026Article
- Ferroptosis and Iron Homeostasis: Molecular Mechanisms and Neurodegenerative Disease Implications.Antioxidants (Basel, Switzerland) · 2025Review
- Nigrostriatal iron accumulation in the progression of Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Multimodal Magnetic Resonance Findings in Parkinson's Disease With "Antecedent Essential Tremor": A Case Series of a Large Kindred.Neuropsychiatric disease and treatment · 2025Article
- Prefrontal cortex iron content in neurodegeneration and healthy subjects: A systematic review.Ibrain · 2025Review
- Spatiotemporal nigrostriatal iron accumulation in motor subtypes of Parkinson's disease: from early to late stage.Brain communications · 2025Article
- Early brain iron changes in Parkinson's disease and isolated rapid eye movement sleep behaviour disorder: a four-year longitudinal multimodal quantitative MRI study.Brain communications · 2025Article
- Exploring the Role of Reactive Oxygen Species in the Pathogenesis and Pathophysiology of Alzheimer's and Parkinson's Disease and the Efficacy of Antioxidant Treatment.Antioxidants (Basel, Switzerland) · 2024Review
- An exploratory research report on brain mineralization in postoperative delirium and cognitive decline.The European journal of neuroscience · 2024Article
- Article
- The Irony of Iron: The Element with Diverse Influence on Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- A rapid multi-parametric quantitative MR imaging method to assess Parkinson's disease: a feasibility study.BMC medical imaging · 2024Article
- Iron Deposition in Parkinson's Disease: A Mini-Review.Cellular and molecular neurobiology · 2024Review
- Glutathione Depletion and Concomitant Elevation of Susceptibility in Patients with Parkinson's Disease: State-of-the-Art MR Spectroscopy and Neuropsychological Study.ACS chemical neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have shown the spatial specificity of cranial iron deposition in different regions in Parkinson's disease (PD). However, the time-specific patterns of iron deposition are not yet clear. The purpose of this study was to investigate the time pattern of iron variations and its clinical relevance in multiple gray matter nuclei in PD using quantitative susceptibility mapping (QSM). Thirty controls and 33 PD patients were enrolled, namely, 11 cases of early stage of PD (ESP) and 22 cases of advanced stage of PD (ASP) according to the Hoehn-Yahr stages. The iron content in the subcortical nuclei covering substantia nigra (SN), red nucleus (RN), head of the caudate nucleus (CN), globus pallidus (GP), and putamen (PT) was measured using QSM, and the clinical symptoms of PD were evaluated by various rating scales. The QSM values in SN, RN, GP, and PT significantly increased in PD patients compared with the controls. Further subgroup comparison with the controls indicated that the iron content in SN and GP (paleostriatum) gradually elevated in the whole disease duration and was related to clinical features. While the iron content in RN and PT (neostriatum) only elevated significantly in ESP patients, further iron deposition was not obvious in ASP patients. Our study confirmed that QSM could be used as a disease biomarker and could be suitable for longitudinal monitoring. However, considering the temporal characteristics of iron deposition in neostriatum, iron deposition in the neostriatum should be paid more attention in the early stage of the disease, even in the preclinical stage, in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.